Curium Knocks Out Novartis Cancer Drug Patents in Generics Fight
核心洞察
A federal judge ruled all patent claims Novartis asserted against Curium and Lantheus over generic Lutathera are invalid due to prior sale exceeding one year before the effective filing date.
The ruling stems from a five-day bench trial in Delaware District Court, where Judge Maryellen Noreika also found Lantheus's generic infringed one patent, though mooted by invalidity.
The decision clears a path for Curium and Lantheus to develop generic cancer therapies rivaling Novartis's Lutathera injection.
A federal judge has invalidated all patent claims that Novartis AG units asserted against Curium Pharma (搜索) subsidiaries and Lantheus Holdings (搜索) Inc., removing a key intellectual property barrier for generic competition to the cancer therapy Lutathera.
Judge Maryellen Noreika of the US District Court for the District of Delaware issued the ruling Wednesday following a five-day bench trial held in December. The court determined that the claims are invalid because the inventions were on sale for more than one year before the effective filing date of the patents.
The ruling also found that Lantheus's proposed generic product infringed one of the patents at issue. However, that infringement finding is rendered moot by the broader invalidity determination, which applies to all claims across the patents.
Implications for the Radiopharmaceutical Market
Lutathera (lutetium Lu 177 dotatate) is a targeted radiopharmaceutical therapy developed by Novartis for the treatment of certain neuroendocrine tumors (搜索). The invalidation of patents covering the product opens the door for Curium and Lantheus to advance their generic versions, potentially introducing pricing competition in a specialized oncology segment.
The on-sale bar, a longstanding principle in US patent law, prevents inventors from obtaining patent protection for inventions that were commercially exploited more than one year prior to filing. Judge Noreika's application of this doctrine proved decisive in the case.
Legal Proceedings and Outcome
The litigation centered on whether Curium and Lantheus infringed valid patent claims held by Novartis units in developing their competing cancer therapies. The five-day bench trial provided the evidentiary foundation for the court's determination that the patents fail to meet the statutory requirements for validity.
With the invalidity ruling, the path forward for generic entrants becomes significantly clearer, though the companies must still navigate regulatory approval processes before bringing their products to market.